Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG5301 anti-BCMA CAR T cells in relapsed/refractory multiple myeloma
2022-500782-27-00Phase 2Completed
- Sponsor
- Lakefront Biotherapeutics
- Start
- Jan 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of GLPG5301 in multiple myeloma (MM), sponsored by Lakefront Biotherapeutics. Primary endpoints: Incidence of adverse events and dose-limiting toxicities (Phase I) and Objective response rate (Phase II). Started Jan 2023; status: completed.
02
Drugs
GLPG5301
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-500782-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500782-27-00.